Cargando…
In Vitro Activities of Enantiopure and Racemic 1′-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis
In the process of evaluating the effect of several plant extracts against Mycobacterium tuberculosis using the Microplate Alamar Blue Assay (MABA), an extract of Thai herb Alpinia galanga rhizome and its major component, 1′-acetoxychavicol acetate (ACA), exhibited marked anti-tuberculosis activity....
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620519/ https://www.ncbi.nlm.nih.gov/pubmed/28927024 http://dx.doi.org/10.3390/scipharm85030032 |
_version_ | 1783267601787387904 |
---|---|
author | Warit, Saradee Rukseree, Kamolchanok Prammananan, Therdsak Hongmanee, Poonpilas Billamas, Pamaree Jaitrong, Sarinya Chaiprasert, Angkana Jaki, Birgit U. Pauli, Guido F. Franzblau, Scott G. Palittapongarnpim, Prasit |
author_facet | Warit, Saradee Rukseree, Kamolchanok Prammananan, Therdsak Hongmanee, Poonpilas Billamas, Pamaree Jaitrong, Sarinya Chaiprasert, Angkana Jaki, Birgit U. Pauli, Guido F. Franzblau, Scott G. Palittapongarnpim, Prasit |
author_sort | Warit, Saradee |
collection | PubMed |
description | In the process of evaluating the effect of several plant extracts against Mycobacterium tuberculosis using the Microplate Alamar Blue Assay (MABA), an extract of Thai herb Alpinia galanga rhizome and its major component, 1′-acetoxychavicol acetate (ACA), exhibited marked anti-tuberculosis activity. The minimal inhibition concentrations (MICs) of the S-enantiomer of ACA (S-ACA) against M. tuberculosis H37Ra ATCC 25177 and H37Rv ATCC 27294 strains were 0.2 µg/mL and 0.7 µg/mL, respectively. More than 95% of 100 drug-sensitive and 50 drug-resistant mycobacterial clinical isolates were inhibited by extracted S-ACA at 1.0 µg/mL. All of the remaining isolates were inhibited at 2.0 µg/mL. In contrast to the S-enantiomer, synthetic racemic 1′-R,S-ACA (rac-ACA) showed MICs of 0.5 µg/mL and 2.7 µg/mL for M. tuberculosis H37Ra ATCC 25177 and H37Rv ATCC 27294, respectively, suggesting that the anti-tuberculosis effect might be primarily due to the S-form. These observations were in line with the MICs of rac-ACA against 98% of 93 drug-resistant clinical isolates, which showed the effective inhibitory dose at 2.0 µg/mL. After exposure to 2.7 µg/mL of rac-ACA for at least 3 h, the tubercle bacilli were completely killed. These demonstrated that ACA had potent anti-TB activity. |
format | Online Article Text |
id | pubmed-5620519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-56205192017-10-06 In Vitro Activities of Enantiopure and Racemic 1′-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis Warit, Saradee Rukseree, Kamolchanok Prammananan, Therdsak Hongmanee, Poonpilas Billamas, Pamaree Jaitrong, Sarinya Chaiprasert, Angkana Jaki, Birgit U. Pauli, Guido F. Franzblau, Scott G. Palittapongarnpim, Prasit Sci Pharm Article In the process of evaluating the effect of several plant extracts against Mycobacterium tuberculosis using the Microplate Alamar Blue Assay (MABA), an extract of Thai herb Alpinia galanga rhizome and its major component, 1′-acetoxychavicol acetate (ACA), exhibited marked anti-tuberculosis activity. The minimal inhibition concentrations (MICs) of the S-enantiomer of ACA (S-ACA) against M. tuberculosis H37Ra ATCC 25177 and H37Rv ATCC 27294 strains were 0.2 µg/mL and 0.7 µg/mL, respectively. More than 95% of 100 drug-sensitive and 50 drug-resistant mycobacterial clinical isolates were inhibited by extracted S-ACA at 1.0 µg/mL. All of the remaining isolates were inhibited at 2.0 µg/mL. In contrast to the S-enantiomer, synthetic racemic 1′-R,S-ACA (rac-ACA) showed MICs of 0.5 µg/mL and 2.7 µg/mL for M. tuberculosis H37Ra ATCC 25177 and H37Rv ATCC 27294, respectively, suggesting that the anti-tuberculosis effect might be primarily due to the S-form. These observations were in line with the MICs of rac-ACA against 98% of 93 drug-resistant clinical isolates, which showed the effective inhibitory dose at 2.0 µg/mL. After exposure to 2.7 µg/mL of rac-ACA for at least 3 h, the tubercle bacilli were completely killed. These demonstrated that ACA had potent anti-TB activity. MDPI 2017-09-18 2017 /pmc/articles/PMC5620519/ /pubmed/28927024 http://dx.doi.org/10.3390/scipharm85030032 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Warit, Saradee Rukseree, Kamolchanok Prammananan, Therdsak Hongmanee, Poonpilas Billamas, Pamaree Jaitrong, Sarinya Chaiprasert, Angkana Jaki, Birgit U. Pauli, Guido F. Franzblau, Scott G. Palittapongarnpim, Prasit In Vitro Activities of Enantiopure and Racemic 1′-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis |
title | In Vitro Activities of Enantiopure and Racemic 1′-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis |
title_full | In Vitro Activities of Enantiopure and Racemic 1′-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis |
title_fullStr | In Vitro Activities of Enantiopure and Racemic 1′-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis |
title_full_unstemmed | In Vitro Activities of Enantiopure and Racemic 1′-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis |
title_short | In Vitro Activities of Enantiopure and Racemic 1′-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis |
title_sort | in vitro activities of enantiopure and racemic 1′-acetoxychavicol acetate against clinical isolates of mycobacterium tuberculosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620519/ https://www.ncbi.nlm.nih.gov/pubmed/28927024 http://dx.doi.org/10.3390/scipharm85030032 |
work_keys_str_mv | AT waritsaradee invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis AT ruksereekamolchanok invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis AT prammananantherdsak invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis AT hongmaneepoonpilas invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis AT billamaspamaree invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis AT jaitrongsarinya invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis AT chaiprasertangkana invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis AT jakibirgitu invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis AT pauliguidof invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis AT franzblauscottg invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis AT palittapongarnpimprasit invitroactivitiesofenantiopureandracemic1acetoxychavicolacetateagainstclinicalisolatesofmycobacteriumtuberculosis |